ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0936

Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis

Andrea Fava1, Jill Buyon2, Chandra Mohan3, Ting Zhang3, H. Michael Belmont4, Peter Izmirly5, Robert Clancy6, Jose Monroy-Trujillo7, Celine Berthier8, Anne Davidson9, Nir Hacohen10, David Wofsy11, Deepak Rao12, Soumya Raychaudhuri13, The Accelerating Medicines Partnership in SLE Network14, William Apruzzese15 and Michelle Petri16, 1Johns Hopkins University, Baltimore, MD, 2Department of Medicine, NYU School of Medicine, New York, NY, 3UT Houston, Houston, 4New York University, New York, NY, 5Department of Medicine, New York University School of Medicine, New York, NY, 6NYU School of Medicine, New York, 7Johns Hopkins University, Baltimore, 8University of Michigan, Ann Arbor, 9Northwell Health, New York, 10Broad Institute, Boston, 11University of California San Francisco, San Francisco, CA, 12Brigham and Women's Hospital, Boston, MA, 13Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 14Multiple Institutions, Multiple Cities, 15., Boston, 16Johns Hopkins University School of Medicine, Timonium, MD

Meeting: ACR Convergence 2020

Keywords: Biomarkers, genomics, Lupus nephritis, proteomics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Plenary Session II (0934–0939)

Session Type: Plenary Session

Session Time: 11:30AM-1:00PM

Background/Purpose: Treatment of lupus nephritis relies on renal histopathological features. However, renal biopsies do not capture patient-specific active biological pathways. Urine proteomic biomarkers could revolutionize the diagnosis and management of lupus nephritis by predicting active intrarenal biological pathways and can be noninvasively monitored over time.

Methods: One thousand proteins were quantified (RayBiotech) in a total of 112 longitudinal urine samples from 30 SLE patients with active lupus nephritis and 7 healthy controls (HC). The proteins and molecular pathways detected in the urine proteome at the time of biopsy were then analyzed with respect to lupus nephritis class, response to treatment after 1 year, histopathological features (activity and chronicity indeces), and trajectory over time (baseline and week 12, 26, and 52). The intrarenal expression of candidate biomarkers was evaluated using single cell transcriptomics of renal biopsies from patients with active lupus nephritis.

Results: There were 237 proteins (FDR < 10%) enriched in the urine of patients with lupus nephritis reflecting several molecular pathways involving chemotaxis, extracellular matrix remodeling, and activation of neutrophils and platelets. Hierarchical clustering using urine proteomics segregated SLE patients into 2 groups, with 80% of complete responders clustering together. This finding could not be similarly reproduced using standard features including baseline proteinuria, creatinine, histologic activity or chronicity scores, or class, indicating unique informative features of urine proteomics (Fig. 1). Patients with proliferative lupus nephritis (class III or IV) had stronger activation of chemotaxis pathways. IL-16 was the urinary protein most significantly increased in proliferative disease compared to membranous (FC 6, p=0.002) (Fig. 2A). Assessment of urine proteins that correlated with histologic activity kidney highlighted IL-16 as the single most strongly correlated protein with histologic activity (r=0.69, p=9.5∙10-5; Fig. 2B). IL-16 concentration was independent of the amount of proteinuria and progressively diminished over time in patients who were responding to immunosuppression (Fig. 2C). Single cell RNA sequencing revealed significant intrarenal expression of IL16 by all infiltrating immune cells and highlighted IL16 as the second most expressed cytokine in lupus nephritis kidneys out of a compendium of 236 cytokines (Fig. 3A-B).

Conclusion: Urine proteomics can noninvasively identify active and biologically relevant pathways in lupus nephritis. Integrated urine proteomics and renal single cell transcriptomics revealed that IL-16, a CD4 ligand with chemotactic and proinflammatory functions, was one of the most expressed cytokine in lupus nephritis. As a urine proteomic biomarker, IL-16 may predict renal histological activity and could be monitored over time to assess response to immunosuppression. Urinary IL-16 is independent of proteinuria thus potentially providing actionable clinical information that is not captured by currently used biomarkers.  Further studies are ongoing to validate these findings.

Figure 1. Concentration of enriched proteomic pathways in lupus neprhitis urine. The relative concentration of the 12 non overlapping pathways (GO Biological Process) enriched in the urine of lupus nephritis (LN) patients is reported in this heatmap. Colors represent row-normalized Z-scores. Unsupervised hierarchical clustering identified the healthy controls and two clusters of LN patients. The LN cluster on the left showed overall lower concentration of proteins in the 12 pathways and included 4/5 of complete responders.

Figure 2. Urinary IL-16 is correlated with renal histological activity and response to treatment. (A) Volcano plot comparing the concentration of 1000 urinary proteins in proliferative vs pure membranous lupus nephritis. (B) Top 20 Pearson’s correlations of urinary proteins with renal histological NIH activity index. IL-16 was the only protein with a false discovery rate (FDR) < 10%. Circle areas represent a combination of the absolute correlation coefficient and p value. (C) Longitudinal trends of urinary IL-16 at baseline, week 12, 24 and 52. Thick lines represent the mean concentration according to the response status at week 52.

Figure 3. Intrarenal expression of IL16 based on single cell RNA sequencing of lupus nephritis kidney biopsies. (A) Violin plots showing IL16 expression by all kidney infiltrating immune cells. (B) Percentage of cytokine positive cells across all kidney infiltrating immune cells. The bar plot shows the top 25 cytokines out of a comprehensive list of 236 obtained from the “Cytokine Registry” (Immport) and the Gene Ontology database.


Disclosure: A. Fava, None; J. Buyon, None; C. Mohan, None; T. Zhang, None; H. Belmont, Exagen Inc, 8; P. Izmirly, GSK, 5; R. Clancy, None; J. Monroy-Trujillo, None; C. Berthier, None; A. Davidson, None; N. Hacohen, None; D. Wofsy, GlaxoSmithKline, 9, Novartis, 9, Principia, 5; D. Rao, None; S. Raychaudhuri, None; T. Accelerating Medicines Partnership in SLE Network, None; W. Apruzzese, None; M. Petri, Astrazeneca, 2, 5, Exagen, 2, 5, GlaxoSmithKline (GSK), 2, 5, Eli Lilly and Company, 2, 5, AbbVie Inc., 5, Aleon Pharma International, Inc, 5, Amgen, 5, Annenberg Center for Health Sciences,, 5, Blackrock Pharma, 5, Bristol Myers Squibb, 5, Decision Resources, 5, Glenmark Pharmaceuticals, 5, INOVA, 5, IQVIA, 5, Janssen Pharmaceutical, 5, Merck EMD Serono, 5, Novartis, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5.

To cite this abstract in AMA style:

Fava A, Buyon J, Mohan C, Zhang T, Belmont H, Izmirly P, Clancy R, Monroy-Trujillo J, Berthier C, Davidson A, Hacohen N, Wofsy D, Rao D, Raychaudhuri S, Accelerating Medicines Partnership in SLE Network T, Apruzzese W, Petri M. Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/urine-proteomics-and-single-cell-transcriptomics-identify-il-16-as-a-biomarker-for-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urine-proteomics-and-single-cell-transcriptomics-identify-il-16-as-a-biomarker-for-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology